Complement Potentiates Immune Sensing of HIV-1 and Early Type I Interferon Responses
Wilfried Posch,
Marta Bermejo-Jambrina,
Marion Steger,
Christina Witting,
Gabriel Diem,
Paul Hörtnagl,
Hubert Hackl,
Cornelia Lass-Flörl,
Lukas A. Huber,
Teunis B. H. Geijtenbeek,
Doris Wilflingseder
Affiliations
Wilfried Posch
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
Marta Bermejo-Jambrina
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
Marion Steger
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
Christina Witting
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
Gabriel Diem
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
Paul Hörtnagl
Central Institute for Blood Transfusion and Immunological Department, Innsbruck, Austria
Hubert Hackl
Institute of Bioinformatics, Biocenter Innsbruck, Medical University of Innsbruck, Innsbruck, Austria
Cornelia Lass-Flörl
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
Lukas A. Huber
Institute of Cell Biology, Biocenter Innsbruck, Medical University of Innsbruck, Innsbruck, Austria
Teunis B. H. Geijtenbeek
Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Importantly, our study highlights an unusual target on DCs—the α chain of complement receptor 4 (CR4) (CD11c)—for therapeutic interventions in HIV-1 treatment. Targeting CD11c on DCs mediated a potent antiviral immune response via clustering of CR4 and CCR5 and subsequent opening of an antiviral recognition pathway in DCs via MAVS.
